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SUMMARY FUNCTIONS FOR DATA IN THE PRESENCE OF
COMPETING RISKS
Yongyun Zhao, PhD
University of Pittsburgh, 2008
Although cumulative incidence function (CIF) estimates are commonly used to describe
the failure probabilities when competing risks are present, the CIF has limitations in some
scenarios. The objective of our research was to propose new summary functions or modify
CIF to overcome the limitations.
In observational studies or nonrandomized trials, CIF estimates can be biased if the
distribution of a confounding variable differs among treatment groups. To reduce the bias,
we developed an adjusted CIF (ACIF) estimator that is based on the use of inverse probability
weighting. We derived the estimation and inference procedures, and then used simulation
studies to evaluate the performance. To illustrate the application of ACIF, we used the
example of liver transplant candidates with various types of end-stage liver disease.
We also developed a series of adjusted survival functions to estimate the “net survival
probability for a specific outcome (the main event), based on the degree of correlation be-
tween this event and the competing events. First, for cases in which there is a perfect negative
correlation, we constructed an adjusted survival function that uses the Kaplan-Meier esti-
mator and the inverse probability of censoring weight (IPCW) for patients who experience
competing events. Second, for cases in which there are imperfect negative correlations, we
constructed an adjusted survival function that uses the combination of the IPCW and the
adjusted number at risk under the constraints of the lower and upper bounds. Third, for
cases in which there are positive correlations, we constructed an adjusted survival function
that uses the adjusted number of main events under the constraints of the lower and upper
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bounds. To recover the contribution that the competing events make to the net survival
probability, we incorporated auxiliary variables into the adjusted number at risk or the ad-
justed number of main events. We derive the estimation and inference procedures. We
demonstrate the use of adjusted survival functions in data derived from patients who had
emphysema, a severe form of chronic obstructive pulmonary disease.
The public significance of this work is to provide new approaches to summarize the
survival data with competing risks.
Keywords: adjusted cumulative incidence function, competing risks, cumulative incidence
function, inverse probability weighting, inverse probability of censoring.
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1.0 INTRODUCTION
A competing risk is defined as an event whose occurrence either precludes or affects the
occurrence of the other event. In the usual competing risk setting, the endpoint consists
of several distinct events of interest and the eventual failure being attributed to one event
exclusively of the others. Under this framework, an individual is exposed to several risks
simultaneously but can only fail from one of these risks. There is an alternative way to define
competing risks, in which an individual may fail from several causes. The current study only
focuses on the usual competing risk setting.
When competing risks are present, a summary function is either used to describe the
time to event for each cause, without focusing on any specific cause or used to describe the
time to event for a specific cause of interest. It is inappropriate to use the complement of the
Kaplan-Meier (KM) estimator, 1−KM, to summarize the data because this method censors
the competing events after they happen and therefore overestimates the failure probability of
the event of interest. Currently, the cumulative incidence function (CIF) is the most widely
used summary function to address these two types of questions. However, the CIF also
suffers from some limitations. When survival data has an unevenly distributed confounder
among groups, the estimated CIF could be biased and misleading. Moreover, the CIF
addresses the marginal failure probability of interest and therefore the resulting function
only presents partial information if the failure probabilities of the competing events do not
present simultaneously. To address these two issues, two new functions are proposed to
summarize survival data with competing risks.
1. In the first part of the study, a new method is developed to estimate the failure proba-
bility of the event of interest when competing risks are present and when the effects of
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confounding variables cannot be ignored. Specifically, instead of using stratification, the
proposed estimator is based on the use of inverse probability weighting. After adjusting
the unbalanced confounder, the selection bias is removed and an unbiased estimator of
the CIF is obtained.
2. In the second part of the study, a series of adjusted survival functions is proposed to esti-
mate the “net” survival probability for a specific outcome (the main event), based on the
degree of correlation between this event and the competing events. The new estimators
are constructed based on Peterson’s bound and the KM estimate. Specifically, we treat
the risks with negative correlation and the risks with positive correlation differently. For
the negative correlation, by using the adjusted number at risk which incorporates the
information recovered from the auxiliary variables for the second event and the inverse
censoring weight, a generalized adjusted survival function is constructed based on the
net survival bound. For the positive correlation, we introduce the net survival bound
first, then a generalized adjusted survival function is constructed by using the adjusted
number at death, which also incorporates the recovered information of the second event
from auxiliary variables.
Two motivational data sets are described in Chapter 2. Previous research on the sum-
mary functions for data with competing risks are presented in Chapter 3. For both of the
proposed summary functions, the derivation of the properties, the inference procedure, and
the simulation plan for assessing the performance of the proposed functions are described in
detail in Chapters 4 and 5. The summary of the current work and the plan for future work
are discussed in Chapter 6.
2
2.0 MOTIVATION DATASETS
2.1 THE LIVER TRANSPLANT DATA FOR THE ADJUSTED
CUMULATIVE INCIDENCE FUNCTION
In the United States, there are more patients on the waiting list for a liver transplant than
the number of organs available. In order to allocate organs in an efficient and appropriate
manner, patients are ordered in the waiting list according to the likelihood that a patient
will die while awaiting transplant. For all patients on the waiting list, some of them may die
before transplant (pre-transplant death), some of them may receive a liver transplant, some
of them may be removed from the list due to other causes (like improvement of disease and
drop out), while the rest of them are alive at the study cutoff time. Therefore, if we are
interested in estimating the probability of pre-transplant death, receiving a transplant and
be removed from the waiting list due to other reasons are competing risks.
Currently, the scores from the model for end-stage liver disease (the MELD scores) are
used to rank the order and the priority of a patient for receiving a transplant. The MELD
score is an index of the severity of the liver disease. The higher the score is, the more likely
the patient will die before receiving a transplant. The MELD score was derived from a
Cox proportional hazards regression model. In this model, time to transplant and time to
removal from the list due to other reasons were both treated as censoring.
There are several different types of liver disease. Severity of illness varies with the
etiology of the liver disease. Therefore, when we compare the probability of pre-transplant
death among different types of liver disease, we have to take into account the different severity
of illness among these groups. In other words, severity of illness measured by the MELD
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score is an unbalanced confounder. The naive CIF estimator cannot be applied without
modification because of this selection bias.
2.2 THE EMPHYSEMA DATA FOR THE ADJUSTED SURVIVAL
FUNCTION
The National Emphysema Treatment Trials (NETT) is the first multi-center clinical trial
designed to determine the role, safety, and effectiveness of bilateral lung volume reduction
surgery (LVRS) in the treatment of emphysema. Patients who met the inclusion criteria
were randomized into the group of using medical treatment only (N=610) or the group of
undergoing surgery in addition to medical treatment (N=608). The trial finished to enroll
patients in July 2002 and followed them up until December 2002. The study found that on
average patients with severe emphysema who underwent LVRS with medical treatment were
more likely to function better, however, the 5-year survival rates between the two groups
were comparable. Although there is no significant survival benefit for patients with LVRS
who under medical treatment, researchers would like to know whether their health-related
quality of life (HRQL) improved significantly compared to those who had medical therapy
only. The HRQL was measured over time using the St. George Respiratory Questionnaire.
If a patient had dropped 8 points of the HRQL measure from the baseline, this patient’s
HRQL considered to have improved significantly. The main study question is to estimate the
probability of HRQL improvement over the 5-year post-randomization follow up period and
to compare the probabilities between the patients assigned to these two treatment groups.
In this study, the main outcome of interest is time to HRQL improvement and death before
reaching the HRQL improvement is a competing risk. Because those who died had worse
HRQL compared to those who lived, death before reaching the HRQL is subject to dependent
censoring. A single summary probability function of HRQL improvement is of main interest
and this estimated function needs to take the dependent censoring due to the competing risk
into account.
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In the liver transplant dataset, our main event of interest is death and the patients’
transplant can be treated as a competing risk. However, once the patient received the trans-
plant, the risk of death changes. So in this case, death after transplant is not unobservable
anymore and the better way to analyze the data is to treat transplant as a time-dependent
variable. We can then test the effect of transplant on the overall survival using the Cox
proportional hazards model.
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3.0 LITERATURE REVIEW
3.1 BASIC CONCEPTS OF COMPETING RISKS
A competing risk is defined as an event whose occurrence either precludes or affects the
occurrence of the other event. In the usual competing risk situation, the endpoints consist of
several distinct events of interest and the eventual failure is attributed to one event exclusive
of the others. Here are two main examples for competing risks:
1. When relapse of a specific disease (such as leukemia, cancer) is the primary event of in-
terest, deaths from other causes (like aging) without relapse of the disease are competing
risks.
2. Another classical example is cause-specific mortality, such as death from heart disease,
death from cancer, death from other causes, etc.
Under the usual competing risk framework, a subject can only fail from one of the many
distinct causes. There is an alternative way to define the competing risk situation when a
subject may fail from several causes. In this paper, our study only focuses on the usual
competing risk setting. In the competing risk setting, a subject is exposed to several risks
simultaneously, and he can either fail from one of the causes or be censored from the study.
So if we have one primary event of interest, we call it the “interest event”, the other risks
are then the “competing risks”.
When competing risks are present, the time-to-event data are complicated because several
distinct risks are acting on a subject at the same time, and the associations among these
risks are not identifiable. Of course, investigators want to answer different questions related
to various research areas. In general, there are two types of situations. One situation is to
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describe the time-to-event change over time for each cause, without focusing on any specific
cause. The other situation is to concentrate on one interest cause, and try to answer questions
around this “interest cause”.
3.2 ASSUMPTION OF INDEPENDENT CENSORING
To understand the censoring mechanism is important in analyzing survival data. There
are many different types of censoring and the most common one is the right censoring,
which refers to censoring that always occurs on the right side of the time continuum. For
individuals with right censoring, we only know that they are still alive before a certain time,
but no information is available about what will happen after that time. In survival data with
competing risks, “right censoring” may alter the hazards of the interest events. Specifically,
if the patients drop out the study in a non-random pattern due to severity of illness, then the
patients remaining in the risk set may be quite different from the original study population.
In this case, we have “dependent censoring” and the censoring mechanism does affect the
analysis results. However, standard methods assume “independent censoring” meaning that
lim
∆→0
P (Ti ≤ t + ∆, R = r|Ti ≥ t)
∆
= lim
∆→0
P (Ti ≤ t + ∆, R = r|Ti ≥ t, Ci ≥ t)
∆
,
where R = r denotes the failure from cause r. Under this model: all cause specific hazards
are independent from whether a subject is censored or not. We need independent censoring
to obtain unbiased and valid estimates for censored survival data.
3.3 CURRENT SUMMARY FUNCTIONS
In general, there are three ways to summarize these data:
1. Analyze the interest event only by treating the events from competing risks as censored
(independent censoring).
2. Analyze one joint endpoint combined by the interest event and competing events.
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3. Analyze the competing risks using the cumulative incidence function.
The first approach is not appropriate because competing risks are dependent with the interest
event, which is known as ”dependent censoring”. The second approach is correct, but it is
not sufficient to address the important aspects of research questions. The third approach
is preferable, but it has some limitations. First, the cumulative incidence function of the
interest event and competing risks should be considered simultaneously in order to address
the failure probability of interest event correctly. Second, the cumulative incidence function
can be biased and misleading if we have an unevenly distributed confounder involved among
groups.
3.3.1 Cause-Specific Hazard
For competing risks problems, we have two different tools to describe the data: the failure
probability and the hazard rate. The hazard function is of the form:
λr(t) = lim
∆→0
P (t ≤ T < t + ∆, R = r|T ≥ t)
∆
For estimation purposes, we can also define it as:
λr(t) = P (T = t, R = r|T ≥ t).
This is the cause specific hazard of cause r at time t. We can estimate this quantity
using the number of events of cause r divided by the number at risk. The semi-parametric
regression models for competing risks focus on modeling the “cause specific hazard”, and a
lot of work has been done in this area.
There are two main disadvantages of the cause specific hazard. First, the hazard is not
intuitively interpretable for the physicians. For competing risks problems, we are usually
interested in summarizing the likelihood of the occurrence of a particular competing risk
instead of the hazard rate. The hazard functions describe the change rate of the failure
probability, they do not quantify the ultimate benefit of the treatment to the patient. Second,
the hazard functions, like the density functions, are difficult to estimate accurately (Pepe
and Mori 1993). And in many cases, the effect of covariates on the failure probability is
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quite different from the effect on the cause specific hazard. Therefore, the estimation of the
failure probabilities becomes our primary goal in presence of the competing risks in most
cases.
3.3.2 Cause-Specific Failure Probability
Klein and Moeschberger (2003) summarized failure probability into three types of probabil-
ities: crude probability, net probability and partial probability.
Crude probability, also called the cause-specific subdistribution function and cumulative
incidence function (CIF), is defined as
Ir(t) = P [T ≤ t, R = r] =
∫ t
0
λr(t)exp{−ΛT (u)}du,
where ΛT (t) =
∑M
r=1
∫ t
0
λr(u)du. The cumulative incidence function is the probability of
death from a particular cause in the real world where all other risks are acting on the indi-
vidual. This is the most acceptable non-parametric estimator in the presence of competing
risks. Ir(t) is a function of hazards of all failure types and is estimable directly without
making any assumption of the joint distribution of the failure times. Also, Ir(t) is a mono-
tone increasing function with Ir(∞) < 1, so that it is not a true distribution function, and
referred to as a “subdistribution function”. Methods of estimating the probability of failure
are discussed in many papers (Dinse and Larson, 1986; Gaynor et al., 1993; Pepe and Mori,
1993; Klein and Moeschberger, 2003) and the inferences of CIF have also been worked out in
this setting (Gray, 1988; Pepe, 1991). Satagopan et al. (2004) gave five steps to calculate the
CIF estimator, they also illustrated nonparametric estimation of CIFs using two published
datasets and compared them with the Kaplan-Meier approach.
CIFs have several advantages. First, they are the unbiased estimators for the probability
of event of interest cause. Second, CIFs are calculated directly from the observed data
without making any assumption about the potential failure times, In other words, CIFs
make no assumption about the association of the interest risk and the competing risks.
Third, CIF estimates are non-parametric estimates, and easy to calculate. However, CIFs
still have some limitations. First, the competing causes of failure are not jointly treated,
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that is, a separate model is fitted for each failure type, treating other failures as censors.
This therefore does not allow for a direct comparison of parameter estimates corresponding
to the various failure types. Second, CIFs are only valid for reference under the same kind
of population with the same setting of competing risks. If the competing risks change with
the different situation, the CIFs are not comparable. Third, the CIF is not a true marginal
distribution, it is only a cause specific failure probability when several causes are acting
together.
The net probability is interpreted as “the death as a result of the cause of interest if the
other competing risks could be removed”. The net probability, Si(t), can be derived as a
marginal distribution from the joint distribution while taking tj = 0 for all j 6= i. In the case
when only one independent competing risk exists, if we treat the competing risk as random
censoring, the net probability can also expressed as a function of the crude probability.
Furthermore, Peterson (1976), Klein (1988), Zheng and Klein (1995) showed that the net
probability is bounded by (1 - the crude probability) and discussed the possible tightness
of bounds under some dependence structures of the joint distribution. The partial crude
probability is the probability of death in the hypothetical world where some competing risks
could be removed. This estimator is similar to the net probability and is barely discussed in
papers.
It is well known that the Kaplan-Meier method is inappropriate for estimating the failure
probability in presence of competing risks (Pepe and Mori, 1993; Klein and Gooley, 1999).
The Kaplan-Meier estimator (Kaplan and Meier 1958), is called the Product-Limit estimator.
This method is widely applied for time-event data with only one endpoint. The censoring
mechanism for the event is restricted to be independent, which means the potential censoring
time is unrelated to the survival outcome. The cause specific failure probability can be
estimated by 1−KM, where KM is the Kaplan-Meier estimator for the survival function of
the cause of interest. It is well known that this is actually a “pure” probability based on a
very strong assumption. When the patient fails at time T , we treat him as being censored
at time T . In reality, this assumption seems too optimistic and untestable.
Gooley et al (1999) pointed out that the censored observations who failed from other
causes led to the biasness of 1−KM and the non-interpretability of the estimator. In practice,
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patients failing from competing risks are treated as censored at the time of failure. In the
competing risks setting, the number of people at risk is reduced by the failure from competing
risks. So the failure probability of interest event should depend on both the hazard rates
of the event of interest and the hazard rates of competing risks. While 1−KM is only the
hazard function of interest event, it overestimates the failure probability. If the competing
risks do not exist, then 1−KM is equal to CIF.
Tai B.C et al (2001) extended the Kaplan-Meier method for the competing risk setting,
where a patient may experience more than one event during the study. They introduced two
ways to handle the data, “ignore” and “censor” methods. For considering failure probability
of type l, in the KM ignore method, all events of type l are included while ignoring all other
non-type l events; in the KM censor method, only the first event of type l is included, and
all non-type l events are censored. We can see that these estimators do not fit in the usual
competing risk frameworks and can not compare with the CIFs.
Pepe and Mori (1993) developed conditional probability estimators, which can be applied
for summarizing failure time data. Let R denote the event of interest, and DR denote the
failure from the remaining events. An estimator of the conditional probability has the form:
ˆCPR(t) =
pˆr(had interest event by t)
1− pˆr(did not have non-interest events by t) =
PˆR(t)
1− PˆDR(t)
,
Where,
PˆR(t) =
∫ t
0
Sˆ−(u)
dNR(u)
Y (u)
, PˆDR(t) =
∫ t
0
Sˆ−(u)
dNDR(u)
Y (u)
.
The authors also discussed the large sample properties of this estimator and presented two-
sample test statistics. Actually this new estimator is a function of the CIFs. It is a monotone
increasing function and can be interpreted as the proportion of patients who had the event
of interest among those who survive from the remaining.
When analyzing survival data with competing risks, we need to notice that: given we
observe (T,R), we can never distinguish dependent competing risks from a pair of inde-
pendent competing risks. This is referred to as the “identifiability dilemma” by Klein and
Moeschberger (2003). In other words, we are unable to analyze associations or relationships
among different risks. Crowder (1994) reviewed problems of “identifiability” in competing
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risks. He also discussed the traditional way of modeling competing risks via latent failure
times.
3.4 INFERENCE TEST FOR COMPETING RISKS
The log rank test is a test of equality of the cause specific hazard (λr(t)) since the cause
specific survival is a simple function of this hazard in the absence of competing risks. When
there are competing risks involved, the CIF or other marginal functions are not a simple
function of the cause specific hazard any more. So the log rank test is invalid for comparing
two CIFs.
Consider the following hypotheses for testing the equality of two CIFs:
H0: I
r
1(t) = I
r
2(t) for all t ≤ τ and
Ha: I
r
1(t) 6= Ir2(t) for some t ≤ τ ,
where τ is the longest time at which both groups have at least one participant at risk. Gray
(1988) proposed a class of generalized linear rank statistics for testing the equality of CIFs.
For comparing the CIFs of two groups, the test was based on a score of the form
∫ τ
0
W (t)[{1− Iˆr1(t−)}−1dIˆr1(t)− {1− Iˆr2(t−)}−1dIˆr2(t)],
where W(t) is a suitably chosen weight function. Basically, the above test compares the
weighted averages of the “sub-distribution hazards”, irk/(1− Irk).
Pepe (1991) proposed a different class of test statistics, not based on ranks, for compar-
ing rather general functions, such as marginal functions (CIFs) and conditional probability
functions. This statistic is the cumulative weighted difference and has the form:
WP = (
n1n2
n1 + n2
)1/2
∫ τ
0
Wˆ (t){Pˆ r1 (t)− Pˆ r2 (t)}dt.
She also showed that, under the null hypothesis of equality, these test statistics are asymp-
totically normal with mean 0, and derived consistent variance estimators. In the Pepe and
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Mori (1993) paper, they chose the weight function
Wˆ (t) = Cˆ−1 (t)Cˆ
−
2 (t)/{
n1
n
Cˆ−1 (t) +
n2
n
Cˆ−2 (t)},
where 1− Cˆ−1 (.) is the left continuous Kaplan-Meier estimator of the censoring distribution
function in the 1st group. This function down-weighs the later time points.
Lin (1997) proposed a resampling technique for developing the approximate distribution
of estimator of CIF. Based on the approximate distribution, the author built the confi-
dence bands for CIF and constructed Kolmogorov-Smirnov type tests for comparing two
CIF curves,
D(t) = W (t)[{Iˆr1(t)− Iˆr2(t)} − {Ir1(t)− Ir2(t)}],
where W (t) is a weight function. Assuming that the observations from the two groups
are independent, use the resampling technique to generate the approximate distributions
of {Iˆr1(t) − Ir1(t)} and {Iˆr2(t) − Ir2(t)} and then evaluate the distribution of D(.). Since
{Iˆr1(t)− Iˆr2(t)}converges to {Ir1(t)− Ir2(t)}, it will be non-zero for some t if H0 does not hold.
Hence the use of the Kolmogorov-Smirnov type statistic
Q = suptW (t)|Iˆr1(t)− Iˆr2(t)|,
will yield an omnibus test, consistent against any alternatives under which Ir1(t) 6= Ir2(t) for
some t within the range of the data.
3.5 SURVIVAL DATA ANALYSIS WITH CONFOUNDERS
A confounder refers to a third variable that can indirectly distort the statistical relationship
between two variables under manipulation or observation. When confounding variables are
present, the estimation of treatment effect can be biased due to the unbalanced distribution
of confounders among groups. For example, in an observational study, we may have more
sicker patients in the treatment group when compared to the control group. When we analyze
the treatment effect based on the original observations, we may conclude that the treatment
is not effective. While it may be due to the selection bias of the patients. Therefore,
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adjusting for confounders is essential for these studies, such as in observational studies and
non-randomized clinical trials.
Traditionally, there are three methods for adjusting covariates in survival data: match-
ing, stratification and semi-parametric models (such as Cox model). Methods of matching
and stratification have been discussed for many studies (Henkey, Myers, 1971; Cupples et
al., 1995; Amato, 1988; Nieto, Coresh, 1996; Winnett, Sasieni, 2002). The basic idea for
matching and stratification is to stratify the patients into strata according to the patients’
confounding variables, so within each stratum, patients have similar characteristics. Then
summarize the survival estimates for each stratum. However, there are some limitations
for matching and stratification, it is often difficult to obtain well-matched data for studies
with small sample sizes. Also, if there are continuous confounders or too many confounding
variables, some strata can have too few individuals to analyze.
The Cox proportional hazards model is widely applied to survival data with a single
endpoint. Recently, this approach has been extended to the competing risks setting. Wei, Lin
and Weissfeld (1988) proposed a method of modeling marginal distributions using the Cox
model for multivariate incomplete failure time data. Lunn and McNeil (1995) used the Cox
regression model by accounting for the censoring in two different ways. One procedure runs
Cox regression stratified by type of failure. The other uses the unstratified Cox regression,
assuming that the hazard functions associated with the two types of failure have a constant
ratio. Cheng, Fine and Wei (1998) introduced a method to construct confidence intervals
and bands for the CIF under the Cox model. The approach was illustrated with data from
a prostate cancer trial. All of these methods are based on modeling the cause specific
hazard (also called “subdistribution hazard”) using the Cox proportional hazards model.
For modeling the cause, r, of cause specific hazard of an individual with covariate vector Z
λr(t|Z) = λr0exp(βrTZ),
where λr0 is the baseline cause specific hazard and β
r is the coefficient vector for cause
r. Unlike survival data without competing risks, we can not construct the ratio of the
cumulative incidence function based on Cox model estimates because the CIF is the function
of hazard of all failure types.
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Fine and Gray (1999) proposed a kind of hazard function, which can be attached to the
cumulative incidence function. They defined their “subdistribution hazard” as
λ1(t;Z) = lim
∆t→0
1
∆t
Pr{t ≤ T ≤ t + ∆t,  = 1|T ≥ t ∪ (T ≤ t ∩  6= 1), Z}
= −dlog{1− I1(t;Z)}/dt,
where I1(t;Z) is the cause 1 cumulative incidence function at time t with covariate Z. The
risk set for the hazard λ1 is unnatural, patients failed before time t due to other causes are
still in the risk set. They also adapted the inverse probability of censoring weight (IPCW)
technique to construct a partial likelihood function for right censored data.
There are two main disadvantages of regression models for adjusting confounders. First,
these models focus on modeling the cause specific hazard, it is not adequate for describing
the overall failure probability. Second, covariates can affect cause specific hazard and failure
probability differently.
Recently, the “propensity score” technique is developed for adjusting confounders. It is
defined as the conditional probability of being in the treatment, exposure or risk group given
the observed covariates. The main idea is: replace the collection of confounding variables
with a single value, which is a function of these covariates representing the “propensity”
to receive the treatment. The propensity score can serve as a “balanced score” for studies
with unbalanced covariates among groups. The inverse probability weighting approach was
originally used in methods to determine the propensity score (Rosenbaum and Rubin, 1983,
1985). Later, inverse probability weighting was widely applied to many research areas,
including the analysis of incomplete data (Wang et al., 1997), the estimation of causal effects
(Dawson and Lavori, 2002; Lunceford and Davidian, 2004), and the analysis of survey data
(Little, 1986).
Xie and Liu (2005) proposed an adjusted Kaplan-Meier estimator (AKME) using the
inverse probability weight to adjust the unbalanced confounders. For the ith individual in
the group k with the covariate Zi, the weight is: wik =
1
pik
= 1
P (Xi=k|Zi) . After assigning
the corresponding weight to each individual, they use the weighted number of events and
weighted number at risk to obtain the adjusted Kaplan-Meier estimator. The following
formula defines the AKME for the kth group:
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Ŝwk (t) =
 1 if t < t1∏
tj≤t[1− dwjk/Y wjk ] if t1 ≤ t
,
The adjusted Kaplan-Meier estimator outperforms the Kaplan-Meier estimator as well as
other estimators based on stratification approaches. The strengths of the inverse probability
weight are: it has good bias reduction and can take account of many covariates. Moreover,
it can be easily performed.
3.6 SURVIVAL DATA ANALYSIS WITH DEPENDENT CENSORING
For survival data with dependent censoring, we can not ignore the information lost due to
censoring. When dependent censoring is present, the usual estimates of survival can be
biased and misleading. Much work has been done to address this issue. Roughly speaking,
there are two types of approaches in this area depending on whether auxiliary prognostic
factors are available or not. When the auxiliary variables are available, under the strong
assumption that the censoring probability can be predicted by these time-dependent and
independent auxiliary variables, the auxiliary variables are incorporated in order to recover
information lost due to censoring and to improve survival estimates (Robins, 1993; Robins
and Finkelstein, 2000; Schafstein and Robins, 2002; Rotnitzky et al.,2007). Some other
useful estimation techniques are also proposed in various studies (Gray, 1992; Finkelstein
and Schoenfeld, 1994; Fleming et al.,1994; Malani, 1995; Murray and Tsiatis, 1996). When
the auxiliary variables are unavailable, based on various assumptions of the dependence
structure of failure time and censoring time, by modeling the joint distribution of failure and
censoring time, many authors evaluated the sensitivity of inference and generated bounds
for the survival function (Slud and Rubinstein, 1983; Klein and Moeschberger, 1988, 1992;
Zheng and Klein, 1994, 1995).
Robins and Finkelstein (2000) developed a weighted Kaplan-Meier estimator using the
inverse probability of censoring weight (IPCW) (Robins, 1993). First, they constructed the
IPCW KM estimator by incorporating the auxiliary variables. Then, they define the weight
16
with this estimator and calculate the weighted survival estimator in the absence of censoring.
The interesting point is that they use the IPCW to construct the weight function and to
incorporate the weight function into the usual Kaplan-Meier formula. Grunkemeier et al.
(2007) proposed a similar method as Robins and Finkelstein’s (2000). They considered the
death from competing risks as dependent censoring and assigned the IPCW weight to each
observed interest event, so that the patients censored due to competing risks were still at risk
for the interest event. The IPCW weight they used was defined as an inverse of the estimated
probability of each interest event being observed given all of the individual’s characteristics
and was derived from the Cox model. The big question in this approach is how to accurately
estimate the probability of each interest event being observed. And accuracy of the IPCW
estimation is strongly dependent on the sufficiency of the auxiliary variables. Specifically, if
the auxiliary variables are sufficient, the hazard of the censoring of event 1 does not depend
on the missing survival time due to the competing risks given the auxiliary variables.
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4.0 PROPOSED STUDY I: ADJUSTED CUMULATIVE INCIDENCE
FUNCTION
4.1 NOTATION
We begin by defining the notation. For an individual i (i = 1, ..., N), let Ti be the possibly
right-censored event time; let δi be the censoring indicator, with δi = 0 if Ti is censored
and with δi = 1 if Ti corresponds to an event. Let Ri indicate which competing events the
individual experienced (Ri = r, where r = 1, ...,M for M different competing events); let Xi
indicate which group the individual belongs to (Xi = 1, ..., K for K different groups); and
let Zi be the covariate vector. Therefore, (Ti, δi, Ri, Xi, Zi) denotes an independent sample
of possibly right-censored survival data with K groups.
The cumulative incidence function (CIF), which is the probability of failure from cause
R = r up to a certain time point t, will be denoted as Ir(t) = P (T ≤ t, R = r) with
r = 1, ...,M . By using the conditional probability, the CIF can be rewritten in the form:
Ir(tj) = P (T ≤ tj, R = r) =
j∑
j′=1
P (T = tj′ , R = r)
=
j∑
j′=1
P (T = tj′ , R = r|T ≥ tj′)P (T ≥ tj′) =
j∑
j′=1
λr(tj′)S(tj′−1). (4.1)
To obtain the CIF estimator, Iˆr(t), we substitute S(t) in equation (1) with the Kaplan-
Meier estimator Sˆ(t) and we substitute λr(tj) in equation (1) with the cause-specific hazard
estimator λˆr(tj) = d
r
j/Yj. The resulting estimated CIF has two properties. One is that
the CIF is directly estimable without making any assumptions about the joint distribution
of the potential failure time of the competing risks. The other is that Fi(t) is not a true
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distribution function, since Fi(∞) = P (δ = i). It has a property that is nondecreasing with
Fi(0) = 0 and Fi(∞) < 1. Such a function is also called a “subdistribution” function.
4.2 PROPOSED FUNCTION
To obtain the weight, we begin by determining the probability that each individual partici-
pant will be in a particular group, conditional on the individual’s characteristics. Individuals
who have a high probability of being in a particular group will be treated as overrepresenting
the group and will therefore receive a lower weight. Individuals who have a low probability of
being in a particular group will be treated as under representing the group and will therefore
receive a higher weight. The weight for any individual for a given group is therefore equal
to the inverse of the probability of being in the group. The weight then is used to adjust
the cause-specific hazard estimator and the Kaplan-Meier survival estimator. Our proposed
ACIF estimator is formed using these two adjusted estimators.
To construct a weight for each individual, let pik be the probability of the ith individual
being in group k. This probability may depend on the covariate vector Zi, i.e., pik = P (Xi =
k | Zi). We will assign the ith individual a weight of wik = 1/pik when this individual is in
the kth group. If there are only two groups involved (such as treatment k = 1 and control
k = 0), then the weight for individual i will be assigned as
 wi1 = 1pi1 = 1P (Xi=1|Zi) if patient i is in the treatment group; andwi0 = 1pi0 = 1P (Xi=0|Zi) if patient i is in the control group. (4.2)
After assigning a weight to each individual, we use the following three steps to construct
the proposed ACIF:
1. Find the adjusted overall survival function.
2. Find the adjusted cause-specific hazard function.
3. Form the ACIF by using the adjusted overall survival function and cause-specific hazard
function from the previous two steps.
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Suppose in a sample that there are D distinct event times t1 < t2 < ... < tD. At time tj
(j = 1, ..., D), in group k there are djk events among Yjk individuals who are at risk. Note
that the risk set Yjk is defined as the number of those who have not experienced any event
by time tj. For each time tj, we let d
w
jk be the weighted number of events and Y
w
jk be the
weighted number of individuals at risk at time tj in group k.
The overall survival function S(t) is defined as the probability of being “event-free” at
time t, where an “event” means any event (the event of interest or a competing event). If
there is only one end point (no competing events), the estimated overall survival function can
be obtained by the Kaplan-Meier estimator. When there is a confounding variable involved,
the Kaplan-Meier estimator needs to be adjusted to avoid bias. Xie and Liu (2005) proposed
an adjusted overall survival function for this situation. To adapt their idea to the case of
multiple end points, we propose to estimate the overall survival function for group k by the
form:
Ŝwk (t) = I(t < t1) + I(t ≥ t1) ·
∏
tj≤t
[1− dwjk/Y wjk ],
where the weighted number of events are
dwjk =
∑
i:Ti=tj
wikδiI(Xi = k) =
∑
i:Ti=tj
δiI(Xi = k)
pik
and the adjusted risk sets are
Y wjk =
∑
i:Ti≥tj
wikI(Xi = k) =
∑
i:Ti≥tj
I(Xi = k)
pik
.
To obtain the adjusted cause-specific hazard function, let r be the event of interest
(r ∈ {1, ...,M}), let drwjk denote the weighted number of events of interest, and again let Y wjk
be the weighted number at risk for group k at time tj. We define the adjusted cause-specific
hazard for the kth group at time tj to be λˆ
rw
k (tj) = d
rw
jk /Y
w
jk , where the weighted number of
events of interest has the form
drwjk =
∑
i:Ti=tj
wikδiI(εi = r)I(Xi = k) =
∑
i:Ti=tj
δiI(εi = r)I(Xi = k)
pik
.
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Finally, we use the overall survival function at time tj−1 and the cause-specific hazard
at time tj to give the form of the ACIF by summing up the product of the overall survival
and cause-specific hazard over time t1, t2, ..., tj. This is the estimator for the probability of
cause r for group k after the unbalanced covariates are taken into account. This process can
be written as:
Iˆrwk (tj) =
j∑
j′=1
λˆrwk (tj′) · Sˆwk (tj′−1). (4.3)
Note that the proposed ACIF in equation (2) tries to add weight to each observation
in the study, where the weight is the inverse probability of the individual being assigned to
group k. When each individual has the same weight (meaning that each individual has an
equal probability of being in each group), then we can prove that the ACIF is reduced to
the CIF estimator.
4.3 PROPERTIES
In Appendix A, we show that given information up to time tj, Ej{Iˆrwk (tj)} = Irwk (tj) where
Ej denotes a conditional expectation. Therefore, in the range where we have data, our
estimated ACIF is an unbiased estimator for the underlying ACIF.
The estimated variance of the CIF has been discussed in several articles (Dinse and
Larson, 1986; Gaynor et al., 1993; Klein and Moeschberger, 2003). Among them, the formula
from Gaynor et al. (1993) is more intuitive. In this article, we use a similar expression for
the estimated variance of our ACIF. The estimated variance of Iˆrw(t), V̂ ar{Iˆrw(t)} is equal
to
j∑
i=1
V̂ ar
{
λˆrwi Sˆ
w(ti−1)
}
+ 2
j−1∑
i=1
j∑
i′=i+1
Ĉov
{
λˆrwi Sˆ
w(ti−1), λˆrwi′ Sˆ
w(ti′−1)
}
.
In Appendix B, we show that the variance and covariance in the above equation can be
estimated by
V̂ ar
{
λˆrwi Sˆ
w(ti−1)
}
=
{
Sˆw(ti−1)
}2
(λˆrwi )
2
[
1− λˆrwi
Miλˆrwi
+
i−1∑
l=1
{
1− sˆw(tl)
Mlsˆw(tl)
}(
1− λˆrwi
Miλˆrwi
+ 1
)]
,
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and
Ĉov
{
λˆrwi Sˆ
w(ti−1), λˆrwi′ Sˆ
w(ti′−1)
}
= λˆrwi λˆ
rw
i′ Sˆ
w(ti−1)Sˆw(ti′−1)[{
i−1∑
l=1
1− sˆw(tl)
Mlsˆw(tl)
+ 1}{1− 1− λˆ
rw
i
Misˆw(ti)
} − 1],
respectively, where Mi = (
∑
j:Tj≥ti 1/pj)
2/
∑
j:Tj≥ti(1/pj)
2 and sw(tl) = S
w(tl)/S
w(tl−1). If
each person in the study has equal weight, we can have Mi = Yi, and the variance and
covariance in the above equation can be further simplified as
V̂ ar
{
λˆri Sˆ(ti−1)
}
=
{
Sˆ(ti−1)
}2
(λˆri )
2
[
Yi − dri
Yidri
+
{
i−1∑
l=1
dl
Yl(Yl − dl)
}(
Yi − dri
Yidri
+ 1
)]
,
and
Ĉov
{
λˆri Sˆ(ti−1), λˆ
r
i′Sˆ(ti′−1)
}
= λˆri λˆ
r
i′Sˆ(ti−1)Sˆ(ti′−1)
[
i−1∑
l=1
dl
Yl(Yl − dl) −
Yi − dri
Yi(Yi − di)
{
1 +
i−1∑
l=1
dl
Yl(Yl − dl)
}]
.
This formula can be used to estimate the variance of CIF, which is very similar to Gaynor’s
(Gaynor et al., 1993). The (1 − α) × 100% pointwise confidence interval for an ACIF is
Iˆrw(t)± Z1−α/2· V̂ ar[Iˆrw(t)]1/2.
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4.4 INFERENCE TEST
Consider the following hypotheses for testing the equality of two ACIFs:
H0: I
rw
1 (t) = I
rw
2 (t) for all t ≤ τ and
Ha: I
rw
1 (t) 6= Irw2 (t) for some t ≤ τ ,
where τ is the longest time at which both groups have at lease one participant at risk.
The test statistic can be written as
WI =
√
n1n2
n1 + n2
·
∫ τ
0
K(t)
{
Iˆrw1 (t)− Iˆrw2 (t)
}
dt, (4.4)
where K(t) is a suitably chosen weight function. This weight function should be a function
of participants at risk in each group at time t, and it should give a lower weight to the later
time points because of the decreasing weight with increasing time. By using K(t), it is easy
to detect an early difference and to stabilize the test statistic.
Pepe (1991) showed that under the null hypothesis of equality, the test statistic is asymp-
totically normal and has a mean of 0. Thus, the test statistic Z0 = WI/
√
V ar(WI) has a
standard normal distribution for large samples under the null hypothesis. Specifically, we
reject the null hypothesis at α level when |Z0| > Zα/2, where Zα/2 is the critical value of the
standard normal distribution.
The hypothesis test of CIFs has been discussed by many researchers (Gray, 1988; Pepe,
1991; Pepe and Mori, 1993; Lin, 1997). Lin (1997) proposed a resampling technique for
developing the approximate distribution of the CIF estimator. Based on the approximate
distribution, Lin built the confidence bands for CIF and constructed Kolmogorov-Smirnov
type tests for comparing two CIF curves. For data with a small or moderate sample size, we
developed a bootstrap approach to test our hypotheses. Given known data with n observa-
tions, we observe individual i as (Ti, di, Xi, Zi), where Ti is the survival time; di is the event
index; Xi is the group index; and Zi is the covariate of the ith participant. The steps of the
bootstrap approach are as follows:
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1. From the n observations, (T1, d1, X1, Z1), (T2, d2, X2, Z2), · · · , (Tn, dn, Xn, Zn), we sam-
ple n times with replacement from this data and form a single bootstrap data set,
(T1∗ , d1∗ , X1∗ , Z1∗), (T2∗ , d2∗ , X2∗ , Z2∗), · · · , (Tn∗ , dn∗ , Xn∗ , Zn∗). For each bootstrap sam-
ple, we use logistic regression to calculate the corresponding weight, w1∗ , w2∗ , · · · , wn∗ .
2. We use the single bootstrap data obtained from step 1 to calculate the estimated ACIF
functions for the event of interest and for the treatment and control groups, Iˆ1w1 (t) and
Iˆ1w2 (t), at each time point. We calculate the test statistic WI
(B) =
√
n1n2/(n1 + n2)∑
K(t){Iˆ1w1 (t)− Iˆ1w2 (t)}.
3. We repeat steps 1 and 2 for B times.
4. From the B bootstrap samples, we calculate the variance of WI(B), V̂ ar{WI(B)}. We
let ZB = WI
(B)/
√
V̂ ar{WI(B)}. Thus, the two-sided P -value of the hypothesis test is
2 · Pr(|ZB| > Zα/2) = (1/B) ·
∑
B I(|ZB| ≥ |Zα/2|).
4.5 SIMULATION STUDIES
4.5.1 Performance of ACIF estimators
In this section, we assessed the performance of the ACIFs for scenarios with highly un-
balanced, intermediate unbalanced, and balanced covariate groups. A sample size of 400
was used. First, we generated the group indicator variable Xi with X = 1 and X = 0
200 times each. Second, we generated the covariate Zi for individual i (i = 1, 2, · · · , 400)
from a Bernoulli distribution with probabilities P = (X = 1|Z = 1) = 0.8 and P = (X =
1|Z = 0) = 0.2 for highly unbalanced data; with probabilities P = (X = 1|Z = 1) = 0.6
and P = (X = 1|Z = 0) = 0.4 for intermediate unbalanced data; and with probabilities
P = (X = 1|Z = 1) = 0.5 and P = (X = 1|Z = 0) = 0.5 for balanced data. Third,
let T1 and T2 denote two lognormally distributed random variables, where Tj = e
Yj and
(Y1, Y2) follows a bivariate normal distribution. Let uj and σj denote the mean and standard
deviation of Yj. We transformed the correlation ρ between Y1 and Y2 into the Spearman
correlation r = (6/pi)arcsin(ρ/2), such that this number was both the Spearman correlation
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between Y1 and Y2 as well as between T1 and T2. In our simulation, we used ρ = 0.5 for the
correlation between Y1 and Y2. If Z = 1, u1 = 2.5, u2 = 1, σ1 = σ2 = 1; if Z = 0, u1 = 0.5,
u2 = 1, σ1 = σ2 = 1. Fourth, create the censoring sample from a uniform distribution. For
the three scenarios, we investigated three censoring rates: 0, 0.2 and 0.4.
To calculate the naive CIF, we used the CIF formula without considering the unbalanced
covariate Z. To calculate the ACIF, we used equation (4.3). To calculate the true underlying
CIF, we used all 400 samples without considering the group factor X because both groups
should have equal CIF.
For each scenario, we plotted the naive CIF, the ACIF, and the true CIF for each
covariate group (Figures 1-3). We also calculated the mean square difference between the
naive CIF and the true CIF and the mean square difference between the ACIF and the true
CIF (Table 1) over all failure times for the event of interest. As shown in Figures 1-3 and
Table 1, the ACIF provided better estimates for the true underlying CIF than the naive CIF
did. The groups that were more unbalanced demonstrated a larger bias when the naive CIF
measures were used. When the percentage of censoring increased, this phenomenon became
more pronounced. When the groups had balanced covariates, both the naive CIF and the
ACIF gave good estimates of the underlying CIF.
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Figure 1. Comparison of the estimated naive CIF, the estimated ACIF, and the underlying
true CIF with highly unbalanced covariate groups.
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Figure 2. Comparison of the estimated naive CIF, the estimated ACIF, and the underlying
true CIF with intermediate unbalanced covariate groups.
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Figure 3. Comparison of the estimated naive CIF, the estimated ACIF, and the underlying
true CIF with balanced covariate groups.
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Table 1. Summary of the mean square difference for the estimated disease-specific cumulative
incidence function (CIF) and the estimated disease-specific adjusted cumulative incidence
function (ACIF)
CIF ACIF
Distribution Censoring Treatment Control Treatment Control
of covariate rate (X=1) (X=0) (X=1) (X=0)
Highly unbalanced
0 0.014 0.011 0.00078 0.00004
0.2 0.015 0.011 0.0011 0.00010
0.4 0.014 0.011 0.0012 0.00005
Intermediate unbalanced
0 0.00033 0.00040 0.00015 0.00013
0.2 0.00032 0.00042 0.00024 0.00013
0.4 0.00071 0.00091 0.00015 0.00009
Balanced
0 0.00005 0.00004 0.00006 0.00005
0.2 0.00005 0.00005 0.00007 0.00012
0.4 0.00009 0.00008 0.00010 0.00017
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4.5.2 Performance of Variance Estimator of ACIF
In this section, we assessed the performance of the variance estimators of ACIFs for scenar-
ios with highly unbalanced, intermediate unbalanced, and balanced covariate groups. The
simulation data were generated using the same procedures as described in section 4.5.1. A
sample size of 400 and censoring rates of 0 and 0.2 were used. Independent samples were
generated for 500 iterations and three time points were investigated, t0 = 1.0, 3.0 and 5.0.
The variance estimators at each time point were calculated using our formula from 500
independent iterations. The mean of these variance estimators was compared with the em-
pirical variance of ACIF (Table 2, Table 3). For both censoring rates, our estimators were
very close to the empirical variance for balanced covariate groups. For the unbalanced covari-
ate groups, our estimators seemed to perform well while the empirical variances were poorly
estimated due to the dependent variance among groups. Moreover, the more unbalanced
covariate was, the larger discrepancy existed between the estimators and the empirical vari-
ances. The empirical variances we obtained were calculated from the variance of the ACIF
for each group from 500 independent iterations. While within each iteration, we calculated
the weight for each individual and split this dataset into two subsets for each of two groups.
Thus, the two subsets are dependent due to the weighting procedure and the ACIF for each
of the two groups are dependent to each other. Eventually, the empirical variance for two
groups were dependent due to the unbalanced covariates distribution among groups. There-
fore, the traditional method of empirical variance was not valid for estimating the variance
of ACIF. In contrast, our variance estimator could be consistent for practical applications.
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Table 2. Summary of the performance of variance estimator compared with the empirical
variance (censoring rate = 0)
Control (X=0) Treatment (X=1)
Distribution Time point var mean var mean
of covariate t0 Iˆ
1w
1 (Iˆ
1w
1 ) (v̂ar(Iˆ
1w
1 )) Iˆ
1w
0 (Iˆ
1w
0 ) (v̂ar(Iˆ
1w
0 ))
Balanced
1.0 0.137 0.000538 0.000583 0.138 0.000561 0.000590
3.0 0.293 0.000825 0.000971 0.293 0.000928 0.000970
5.0 0.339 0.000869 0.000994 0.338 0.000997 0.000992
Intermediate
1.0 0.138 0.000452 0.000624 0.139 0.000697 0.000609
unbalanced
3.0 0.295 0.000670 0.00105 0.294 0.000980 0.000976
5.0 0.341 0.000817 0.00109 0.339 0.000987 0.000990
Highly
1.0 0.137 0.000362 0.000964 0.139 0.00140 0.000887
unbalanced
3.0 0.295 0.000574 0.00170 0.294 0.00159 0.00136
5.0 0.340 0.000713 0.00178 0.339 0.00155 0.00135
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Table 3. Summary of the performance of variance estimator compared with the empirical
variance (censoring rate = 0.2)
Control (X=0) Treatment (X=1)
Distribution Time point var mean var mean
of covariate t0 Iˆ
1w
1 (Iˆ
1w
1 ) (v̂ar(Iˆ
1w
1 )) Iˆ
1w
0 (Iˆ
1w
0 ) (v̂ar(Iˆ
1w
0 ))
Balanced
1.0 0.119 0.000589 0.000571 0.120 0.000501 0.000572
3.0 0.270 0.00101 0.00109 0.271 0.000786 0.00110
5.0 0.318 0.00119 0.00118 0.319 0.000955 0.00118
Intermediate
1.0 0.121 0.000458 0.000584 0.119 0.000646 0.000582
unbalanced
3.0 0.272 0.000820 0.00114 0.271 0.00121 0.00109
5.0 0.320 0.000998 0.00116 0.319 0.00125 0.00116
Highly
1.0 0.119 0.000343 0.000939 0.121 0.00120 0.000856
unbalanced
3.0 0.269 0.000747 0.00192 0.274 0.00189 0.00151
5.0 0.318 0.00103 0.00213 0.322 0.00202 0.00156
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4.6 ANALYSIS OF LIVER TRANSPLANT DATA
In this section, we use data derived from the Organ Procurement and Transplantation Net-
work (2004) to demonstrate how an unbalanced distribution of a confounding variable affects
the estimated CIF and to show how our proposed ACIF is used. The data are for candidates
on the waiting list for a liver transplant. The candidates include 6,114 adults (aged 16 years
or older) who had various types of end-stage liver disease, joined the waiting list at any time
in year 2002, and were followed until January 31, 2004.
Our main covariate of interest was the variable indicating 10 disease types, and the
confounding variable was the score derived from the model for end-stage liver disease (MELD
score). In the analytic data set used here, we excluded 462 patients with unknown disease
type, unknown MELD score, or unknown reasons for removal from the waiting list. Among
the remaining 5,652 patients, 563 died before receiving a transplant (pre-transplant death),
2,308 received a transplant, 207 were removed from the waiting list for reasons other than
death or transplant (e.g., they experienced an improvement in health that changed their
need or desire for a transplant), and 2,574 were alive and still waiting for a transplant at the
time of the study cutoff (Figure 4).
The distribution of the MELD scores for each of the 10 disease types is summarized in
Table 4. Note that the MELD score ranges from 6 to 40, with 6 indicating the least ill
patient and with 40 indicating the sickest patient. We found that patients with alcoholic
liver disease and patients with metabolic liver disease had the highest mean MELD scores,
while patients with liver cancer had the lowest mean MELD score. Patients with other liver
disease types had similar mean MELD scores. For each of the 10 disease types, Figure 5
depicts the estimated CIF and Figure 6 depicts the estimated ACIF. As shown in Figure 7,
although the estimated CIFs differed for patients with primary biliary cirrhosis and differed
from those of patients with alcoholic liver disease (P = 0.016), the estimated ACIFs for these
groups did not differ (P = 0.23). And although the estimated CIFs for patients with primary
sclerosing cholangitis differed from those of patients with alcoholic liver disease (P = 0.006),
the estimated ACIFs for these groups did not differ (P = 0.24).
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To estimate the ACIFs and to test whether the CIFs or ACIFs were equal among the
10 disease groups, we expanded equation (4.2) and used multinomial logistic regression to
obtain the weight for each patient by estimating the probability that the patient would have
a specific type of liver disease given his or her MELD score. For the post hoc comparison
of CIFs and ACIFs in paired groups, we used the weights obtained from regular binomial
logistic regression. The bootstrap sample size B used in the example was 1,000.
Because the data might violate the proportional hazards assumption, we used the weight
function K(t) = nC∗1(t)C
∗
2(t)/{n1C∗1(t) + n2C∗2(t)} in equation (4.4) for the adjustment.
This weight function is 1 minus the left continuous Kaplan-Meier estimator of the censoring
distribution function, where C∗1(t) and C
∗
2(t) are the censoring distribution and where n1
and n2 are the sample sizes for the two disease groups.
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Table 4. Scores Derived from the Model for End-stage Liver Disease (MELD Scores) and
Distributed among Patients with Ten Types of Liver Disease
Figure 4. Conditions for the last follow-up.
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Figure 5. Estimated disease-specific cumulative incidence function.
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Figure 6. Estimated disease-specific adjusted cumulative incidence function.
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Figure 7. Comparison of the estimated disease-specific cumulative incidence function (CIF)
and the estimated disease-specific adjusted cumulative incidence function (ACIF).
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4.7 DISCUSSION
There are several different versions of the estimated variance of CIF. In general, these esti-
mates can be classified as: the approaches based on counting process or martingale theory
(Aalen, 1978; Pepe, 1991; Gray, 1988) and the approaches based on moments of the multi-
nomial distribution (Dinse and Larson, 1986; Gaynor et al., 1993). Klein and Moeschberger
(2003) proposed another kind of formula that estimated the variance as a function of the CIF.
Braun and Yuan (2007) found that the multinomial-moment-based estimators outperformed
than the others, especially for small sample size. Therefore, in our study, we adapted the
idea of multinomial-moment-based approaches from Gaynor et al. (1993). When there are
no unbalanced covariates involved among groups, our variance estimator can be simplified
to a formula similar to Gaynor’s. Our simulation study also showed that the traditional em-
pirical variance from bootstrap methods performed poorly due to the dependence of ACIF
among groups.
To compare two ACIFs, we developed a test statistic that is based on a generalized
test for stochastic ordering of functions. This kind of test was originally proposed by Pepe
and Fleming (1989), who used the non-parametric weighted Kaplan-Meier estimator to test
for the difference between two survival functions. We are currently developing another test
statistic that will be based on generalized linear rank statistics and will be a modification of
Gray′s (1988) tests. For a discussion of the differences between statistics based on stochastic
ordering and statistics based on linear rank tests, see Pepe and Fleming (1989, 1991).
In this study, we used only one example of the weight function K(t) in equation (4.4). The
weight function was a positive function, with lower weights reflecting smaller sample sizes
as time progresses. Because the choice of K(t) will affect the stability and interpretability
of the results, we will be exploring other choices in future studies.
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5.0 PROPOSED STUDY II: ADJUSTED SURVIVAL FUNCTION
5.1 INTRODUCTION
The cumulative incidence function is a marginal distribution, which estimates the cause
specific failure probability when the patients are exposed to two or more risks simultaneously.
Therefore, the CIF of the event of interest is affected by the occurrence of the competing
event and it only presents partial information if the failure probabilities of the competing
events do not present simultaneously.
For survival data with competing risks, most of the time we still want to answer: “what
is the failure probability of our cause of interest if there are no competing risks?”. In this
case, the net survival probability S1(t) = Pr(T1 ≥ t) is more appropriate and it is a marginal
survival function after removing the effects of competing risks. It is inappropriate to use the
complement of the Kaplan-Meier (KM) estimator, 1−KM, to summarize the data because
this method censors the competing events right after they happen and therefore it assumes
“independent censoring” for the competing events. While in most cases, competing risks can
not be treated as “independent censoring” since there is usually some dependence structure
between the main event and the competing events. We can not obtain the net survival
probability for the event of interest given the data since we only observe the failure time of
competing events and miss the potential failure time caused by the main event.
According to Peterson (1976), the net survival probability of event 1 should be bounded
between ST (t) ≤ S1(t) ≤ 1−I1(t) if the risks are dependent. The lower bound is the survival
of min(T1, T2). In other words, it is the overall survival function, which treats both event
1 and event 2 as events. The upper bound is the complement of the CIF of the event of
interest. When the two events (risks) have perfect positive (negative) correlation, the net
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survival probability should be exactly equal to the lower (upper) bounds. Researchers (Klein
and Moeschberger,1988; Zheng and Klein, 1994) have tightened the bounds and performed
inference tests by assuming a dependence structure for the joint distribution of the competing
risks. Therefore, the dependence structure of the events is the key point for determining the
net probability. However, the dependence structure is “unidentifiable” based on the observed
survival time and event.
To estimate the survival function, some early works focused on constructing the censoring
models (Williams, Lagakos, 1977; Lagakos, Williams, 1978; Link WA, 1984). Williams
and Lagakos’s “cone-class” censoring models need the assumption of the distribution of the
survival function involved with parameter estimation from the likelihood, while Link’s frailty
censoring model needs the frailty assumption. Recently, “auxiliary variables” have been
introduced to recover missing information due to the dependent censoring. When auxiliary
variables are available, Robins and Rotnitzky (1992), Robins (1993), Satten et al (2001), and
Robins and Finkelstein (2001) proposed useful techniques to incorporate these variables and
recover the information of the dependence structures. By utilizing the auxiliary variables,
the survival estimates can be adjusted and imposed efficiently. However, these approaches
do not distinguish the dependent and independent censoring and therefore the following
estimates are strongly dependent on the sufficiency of the auxiliary variables.
In this paper, we propose new approaches to obtain the net survival probability estimators
under various negative/positive correlation structures. First, for data with perfect negative
correlation, we proposed an adjusted survival estimator, which is equivalent to 1-CIF. This
adjusted survival function was constructed based on the Kaplan-Meier estimator by utilizing
the Inverse Probability of Censoring Weight (IPCW) to adjust the potential censoring status
for event 2 persons after their event 2 time. Second, after introducing the bounds for negative
correlation, the adjusted survival function for negative correlation was proposed by using the
adjusted number at death. Specifically, for the event 2 subjects, their censoring status was
adjusted by assigning a new weight function which is a linear function of the IPCW and
an index of auxiliary variables. Third, by introducing the bounds for positive correlation,
the adjusted survival function for positive correlation was constructed using the adjusted
number of events. This adjusted number of events takes account of the potential occurrence
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of event 1 from event 2 persons. And the auxiliary variables were incorporated to recover
this information. The properties of these adjusted survival functions have been derived.
Modified log rank tests are proposed to test the equality of two adjusted survival functions.
5.2 METHOD
5.2.1 Notations
To simplify, we call event 1 the event of interest; and call event 2 for the other event(s) due
to competing risk(s). Let (Ti, δi, i) denote an independent sample of right-censored survival
data; where Ti is the possibly right censored event time; δi is the censoring indicator, δi = 0 if
Ti is censored and δi = 1 if Ti corresponds to an event; i is the event indicator, i = 1 means
the ith patient has event 1; i = 2 means the ith patient has event 2. Also, suppose in this
data that there are D distinct event 1 times t1 < t2 < · · · < tD and that the total number
of patients is Y at the beginning of the study. Let ej be the number of deaths (observed,
from event 1 persons), and e′2j be the number of deaths (unobserved, from event 2 persons)
at time tj; let r
∗
j be the number of observations censored (unobserved, from event 2 persons)
at time tj.
5.2.2 Inverse Probability of Censoring Weight (IPCW)
The inverse probability of censoring weight (IPCW) was first presented by Robins and Rot-
nitzky (1992). Gray and Fine (1999) adapted their idea and created a function of IPCW
for the event 2 patients when they constructed the partial likelihood of the sub-distribution
(CIF). As we mentioned before, when event 1 and event 2 have perfect negative correlation,
which means event 2 subjects have no chance to experience event 1 in the unknown future
time, the net survival probability is equal to 1-CIF.
For the events with perfect negative correlation, we can impute the censoring status for
the event 2 subjects using the inverse censoring probability. Our basic idea is:
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1. Subjects who experience event 2, are treated as if they will experience event 1 at time
t = ∞. Thus, with respect to event 1, the problem is transformed to a univariate case,
where it is assumed that every subject will eventually experience an event 1.
2. For the ith person who experienced event 2 at time Ti < t, it is unknown whether this
person would be censored at the analysis time t. But we know that this person is still
free of event 1 at time Ti. For any t > Ti, we assign a weight 0 < wi < 1. And the weight
is a function of an inverse probability of censoring.
Our IPCW weight for the event 2 person is given by
wi(t) =
 0 if t ≤ Ti1− P (C>t)
P (C>Ti)
if t > Ti
.
This function is increasing as analysis time, t is increasing. Specifically, this weight is
a “censoring weight”, it is an estimated probability of the potential censoring status for an
event 2 subject at each analysis time t. For an event 2 patient, his censoring weight is 0 before
he experiences event, so he is in the risk set with a weight of 1; after the occurrence of event
2, he is in the risk set with a weight less than 1 depending on the censoring distribution and
his event 2 time. Satten and Datta (2001) showed that the Kaplan-Meier estimator could
be used as an inverse probability of censoring weighted average. Thus, to get the weight, we
can use the Kaplan-Meier method to obtain the distribution of censoring, then calculate the
weight at each time. Specifically, we can treat censoring as an event, while event 1 and 2 as
censoring, then we perform the regular Kaplan-Meier analysis using a standard statistical
package.
5.2.3 Adjusted Survival Function for Perfect Negative Correlation
We start from the situation with perfect negative correlation. In this case, event 2 persons
have no chance of getting event 1 in the unknown future time. Here we propose an adjusted
survival estimator which is extended from the Kaplan-Meier framework. In our approach,
we focus on interpreting the effect of event 1 after we take account of the event 2 patients.
In this adjusted survival function, the numerator is the number of deaths (event 1) at each
time tj, this should have no unobserved event from event 2 persons; the denominator is the
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adjusted number at risk, we adjust the weight at risk set for event 2 persons using our IPCW
weight.
Our proposed adjusted survival estimator of event 1 is given by
Sˆ ′1(t) =
D∏
j=1
(1− ej
Y ′j−1
), (5.1)
where Y ′j = Y −
∑j
k=1(ek + ck)− r′j.
Using the index function, we can rewrite the ek, ck, rk as follows
ek =
∑
i:Ti=tk
δi · I(i = 1)
r′j =
∑
i:Ti<tj
wi(tj)δi · I(i = 2)
ck =
∑
i:tk−1≤Ti<tk I(δi = 0),
where wi(t) is the weight function for the ith individual who experienced event “2” and
0 < wi(t) < 1. It is a time dependent function of Ti and tj. So for each event 2 subject,
there can be a different wi at different analysis times.
This adjusted survival function is a net survival estimator for events with perfect negative
correlation. For event 2 persons, their censoring starts to happen right after their event 2
time, and the censoring probability follows our IPCW over time. Their weight in the risk
set is decreasing as time increases after the event 2 time.
The adjusted survival function we proposed is an estimated “net survival” under the
assumption of perfect negative correlated risks. Therefore, it should be equivalent to 1−CIF.
Here is the short proof to show this equivalence. The net survival of event 1 can be written
as
Sˆ1(t) =
D∏
j=1
(1− ej + e
′
2j
Y −∑jk=1(ek + ck)− r∗j ). (5.2)
If the risks are perfectly negatively correlated,
1− I1(t) = S1(t),
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and e′2j = 0. Thus,
Sˆ1(t) =
D∏
j=1
(1− ej + e
′
2j
Y −∑jk=1(ek + ck)− r∗j )
=
D∏
j=1
(1− ej
Y −∑jk=1(ek + ck)− r∗j ), (5.3)
And this net probability of event 1 has the same formula as our proposed adjusted
survival function in (5.1). As far as we can correctly estimate r∗j for event 2 persons, our
adjusted survival function should be equivalent to 1-CIF. As we mentioned previously, the
r′j was constructed via the censoring weight and it should converge to the r
∗
j as the sample
sizes increase.
5.2.4 Adjusted Survival Function for Various Negative Correlation
The adjusted survival estimator in (5.1) is only valid for the perfect negative correlation.
In this section, we try to extend this adjusted survival estimator for events with various
negative correlation patterns. As we mentioned before, if the risks are negatively correlated,
the bounds can be further written as: SKM(t) ≤ S1(t) ≤ 1− I1(t). The lower bound is the
situation with independent censoring for the event 2 subjects, where the event 2 subjects are
censored right at their event 2 time. We can substitute the upper bound with our proposed
adjusted survival function. Therefore,
SKM(t) ≤ S1(t) ≤ S ′1(t).
In this case, the upper bound (independent risks) and lower bound (perfect negative
correlation) are determined. The underlying true net survival should lie between these
two bounds if the risks have unknown negative correlation. No matter what this survival
distribution looks like, we always can create an adjusted survival function to approach it.
With the sample size large enough, the survival curve should look smooth.
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Comparing the upper bound with the lower bound, the only difference comes from the
“number at risk”. In the lower bound, the risk set is equal to
Yj = Y −
j∑
k=1
(ek + ck)− rj,
where rj =
∑
i:Ti<tj
δi · I(i = 2). While in the upper bound the risk set is equal to
Y ′j = Y −
j∑
k=1
(ek + ck)− r′j,
where r′j =
∑
i:Ti<tj
wi(tj)δi · I(i = 2).
If the dependence structure exists, the difference must reflect the contribution of event 2
in the risk set. And the “censoring contribution” should between rj and r
′
j. Specifically, for
the ith event 2 person, the censoring status at time t (t > Ti) should between 1 and wi(t),
and this status is also affected by the dependence structure of the risks. Therefore, for the
ith event 2 individual, we construct a specific wgi (t)
wgi (t) = pi ∗ 1 + (1− pi) ∗ wi(t) if t > Ti, (5.4)
where pi = Pr(ith event 2 individual would experience event 1|~Zi), ~Zi is a vector of auxil-
iary variables. This pi can be derived from the logistic regression, with ~Zi as the independent
variable. The data for this regression can be obtained from the original dataset excluding
the event 2 subjects. We can code event 1 as 1 and censoring as 0. The predicted pi for
the ith event individual can be obtained from the logistic regression equation. It should be
noticed that ~Zi needs to be sufficient to predict the likelihood of event 2 persons experienc-
ing event 1. Specifically, given the auxiliary variables ~Zi, the probability of event 2 subjects
experiencing event 1 does not depend on the unobserved times.
To obtain the generalized adjusted survival function for various dependence structures ,
we replace the wi(t) with w
g
i (t) in the censoring part of event 2 subjects. Thus,
r′j =
∑
i:Ti<tj
wgi (tj)δi · I(i = 2), (5.5)
and following equation (5.1), we calculate the survival function.
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If for each event 2 individual, pi = 1 and w
g
i (t) = 1, our adjusted survival function
approaches the lower bound Sˆ ′1(t) = SKM . If for each event 2 individual, pi = 0 and
wgi (t) = wi(t), our adjusted survival function converges to the upper bound.
In our generalized adjusted survival function, the “pseudo-like” censoring part from event
2 subjects is not a traditional censoring status for these patients. In traditional Kaplan-
Meier survival, the censoring part does not have an event, these persons are lost to follow-up
randomly. While in our approach, since we incorporated one “pseudo-like” censoring part
to adjust both the potential death or censoring, this part has to include both the potential
death and censoring information. Therefore, this penalty part is not the typical part of
censoring anymore, it is a combination factor depending on the missing death or censoring.
In our approach, we actually constructed hypothetical survival curve to approach the true
underlying survival. The form of wgi (t) is a linear combination of pi and wi(t). The impact
of a different choice of this form should be further investigated via simulation studies.
5.2.5 Adjusted Survival Function for Various Positive Correlation
When the risks are positively correlated, the upper and lower bound of the net survival of
event 1 is:
ST (t) ≤ S1(t) ≤ SKM(t).
Therefore, for any unknown positive correlation, the net survival should lie between the
upper and lower bound. When the risks have perfect positive correlation, the net survival
equals the lower bound, which is the overall survival and treats both event 1 and event 2 as
an event. When the risks are independent, the net survival reaches the upper bound, the
KM survival, which treats event 2 as censoring right at their event 2 time.
Comparing the upper and lower bound, we find that: the only difference of these bounds
comes from the difference in the numerator. Here e2j is the number of deaths due to event
2 during time interval tj−1 to tj. The lower bound can be written as
SˆT (t) =
D∏
j=1
(1− ej + e2j
Yj−1
), (5.6)
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while the upper bound is
SˆKM(t) =
D∏
j=1
(1− ej
Yj−1
), (5.7)
where Yj = Y −
∑j
k=1(ek + ck)− rj.
Using the index function, we can rewrite the ek, ck, and rk as follows
ek =
∑
i:Ti=tk
δi · I(i = 1)
rj =
∑
i:Ti<tj
δi · I(i = 2)
ck =
∑
i:tk−1≤Ti<tk I(δi = 0)
e2j =
∑
i:tj−1<Ti≤tj δi · I(i = 2).
Obviously, the difference between the upper and the lower bound is the number of deaths
due to event 2 subjects. With the perfect positive correlation, the event 1 time for the event
2 subjects is equal to their event 2 time. If we want to recover the net survival for data with
unknown positive correlation, we can define an adjusted survival function which is similar in
form to the upper and lower bound, the key point is to find the adjusted number of deaths
due to event 2 subjects (unobserved) at each time interval from tj−1 to tj. And this quantity
is unidentifiable given the observed survival time and event. Similarly as in the previous
part, we need to borrow information from the auxiliary variables. If, given the auxiliary
variables, the hazard of event 1 does not depend on the unobserved censoring or event, then
these auxiliary variables are sufficient to recover the missing event 1 information due to
competing risks.
Suppose the ith event 2 person experienced event 2 during time tj−1 to tj. From the
upper and lower bound, we can see that this person is out of the risk set, but whether he
experiences event 1 or censoring is not certain. Therefore, we can use the auxiliary variable
to predict the potential probability of experiencing event 1 and the adjusted number of event
1 due to event 2 persons has the form
e′2j =
∑
i:tj−1<Ti≤tj
piδi · I(i = 2) (5.8)
where pi = Pr(ith event 2 individual would experience event 1|~Zi) and ~Zi is a vector of aux-
iliary variables. This pi has the same definition as the one we used in the negative correlation
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case and can be obtained via the approach we described previously. The adjusted survival
function for positive correlation can be obtained from
Sˆ ′1(t) =
D∏
j=1
(1− ej + e
′
2j
Yj−1
). (5.9)
If pi = 1 for each event 2 individual, our adjusted survival function approaches the lower
bound Sˆ ′1(t) = ST (t). If pi = 0 for each event 2 individual, our adjusted survival function
converges to the upper bound Sˆ ′1(t) = SKM(t).
5.3 PROPERTIES
5.3.1 Mean and Variance
In this section, we start to derive the properties for the adjusted survival function with
negative correlations.
We define s′j = S
′1(tj)/S ′1(tj−1), and its adjusted estimator is ŝ′j = 1− ejY ′j−1 and Ej is a
conditional expectation given information up to time tj. First, we show that ŝ
′
j is unbiased,
and then show that Ŝ ′1(tj) is unbiased by means of successive conditional expectation, that
is,
Ej{1− ŝ′j} = Ej(
ej
Y ′j−1
|information up to time tj)
=
(1− s′j) · Y ′j−1
Y ′j−1
= 1− s′j.
Here the expected number of deaths at time tj is equal to the probability of death multiplied
by the number at risk and we plug in the new adjusted number at risk instead of the usual
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one. Following the above notation, by means of successive expectations, we obtain
E{Ŝ ′1(tj)} = E{ŝ′1 · · · ŝ′2 · ŝ′j−1 · E(ŝ′j)}
= E{ŝ′1 · ŝ′2 · · · ŝ′j−1} · s′j
= E{ŝ′1 · ŝ′2 · · · ŝ′j−2} · E(ŝ′j−1) · s′j
= s′1 · s′2 · · · s′j
= S ′1(tj).
From the above proof, we can show that the adjusted survival function can be unbiased if
the weight is proper. From the successive expectations, the estimator is appropriate whenever
tj is less than the maximum event 1 time.
Now we can derive the variance formula of this adjusted survival function
E{Sˆ ′1(t)}2 =
∏
j:Tj≤t
Ej(Sˆ
′1
j )
2
=
∏
j:Tj≤t
{S ′1j + V arj(Sˆ ′1j )}
=
∏
j:Tj≤t
{(S ′1j )2 +
S ′1j (1− S ′1j )
Y ′j
}
= (S ′11 )
2...(S ′1k )
2
∏
j:Tj≤t
{1 + 1− S
′1
j
Y ′jS
′1
j
}
= {S ′1(t)}2
∏
j:Tj≤t
(1 +
1− S ′1j
Y ′jS
′1
j
).
By the definition of the variance, we can get
V ar{Sˆ ′1(t)} = E{Sˆ ′1(t)}2 − [E{Sˆ ′1(t)}]2
= S ′1(t)2{
∏
j:Tj≤t
(1 +
1− s′j
Y ′j s
′
j
)− 1}. (5.10)
Following the same approach, we also can show that our adjusted survival for positive
correlation is unbiased. And the variance formula can also be derived in the same way except
Y ′ is replaced by Y in equation (5.10).
50
5.3.2 Confidence Interval
The (1−α)×100% pointwise confidence interval for an adjusted survival function is Sˆ ′r(t)±
Z1−α/2· V̂ ar[Sˆ ′r(t)]1/2.
5.4 MLE OF PSEUDO-LIKELIHOOD
For right-censored data in the absence of competing risks, we can write the likelihood with
respect to the survival function. For patients who experience the event, we use the density
function; for the patients who are censored, we use the survival function. With right-censored
data in the presence of competing risks, we can write a “pseudo-likelihood” with respect to
the adjusted survival function for event 1. In this case, we still use the density function for
subjects who experience event 1, and the survival function for “true censoring”. But for the
subjects who experience event 2, their censoring times are unknown, and the event 1 times
are unobserved. For data with negative correlation, we can treat event 2 subjects as being
partially censored at each time point (event 1 time) with weight wgi (t). Similarly, for data
with positive correlation, we can treat event 2 subjects as a partial event with weight pi and
as partially censored with weight 1− pi.
5.4.1 MLE of Pseudo-likelihood for Negative Correlation
Let t1 < t2 < · · · < tk, denote the distinct event 1 times; λj denote the number of true
censored times in [tj, tj+1); rj denote the number of event 2 subjects during [tj, tj+1); w
g
i
denote vector of the weights for the ith person. For the ith person, wgi (tj) is a different
weight at each time point tj. A pseudo-likelihood with respect to S(t) (here S(t) refers to
the adjusted survival S ′(t)) is then defined as:
n∏
i=1
[Si(Ti − 0)− Si(Ti)]δiI(i=1)[Si(Ti)](1−δi)[Si(Ti)]δiI(i=2)w
g
i . (5.11)
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We can rewrite the pseudo-likelihood in terms of Kaplan-Meier as
L{S(t)} =
λ0∏
i=1
{S(L(0)i )} ×
r0∏
i=1
{S(L(0)i )}w
g
i (t1)δiI(i=2) × {S(t1 − 0)− S(t1)}
P
i:Ti=t1
δiI(i=1)
×
λ1∏
i=1
{S(L(1)i )} ×
r0+r1∏
i=1
×{S(L(1)i )}w
g
i (t2)δiI(i=2) × {S(t2 − 0)− S(t2)}
P
i:Ti=t2
δiI(i=1)
· · · ×{S(tk − 0)− S(tk)}
P
i:Ti=tk
δiI(i=1) ×
λk∏
i=1
{S(L(k)i )} ×
r0+r1+···+rk∏
i=1
{S(L(k)i )}w
g
i (tk+1)δiI(i=2).
For right-censored data, we know that
S(L
(0)
i ) = S(t1 − 0) = 1 and S(tj) = S(L(j)i ) = S(tj+1 − 0).
So (5.11) can be rewritten as
k∏
j=1
(Sj−1 − Sj)
P
i:Ti=tj
δiI(i=1) × (Sj)
Pλj
i=1 × (Sj)
P
i:Ti<tj
wgi (tj)δiI(i=2). (5.12)
From the property of the Kaplan-Meier estimator, let sj = Sj/Sj−1, Sj = s1.s2...sj , so
Sj−1 − Sj = s1...sj−1(1− sj) and (5.12) can be written as
 L(Sj) =
k∏
j=1
(1− sj)
P
i:Ti=tj
δiI(i=1) · (sj)
Pk
l=j+1{
Pλl
i=1+
P
i:Ti=tl
δiI(i=1)+
P
i:Ti<tl
wgi (tl)δiI(i=2)}
· (sj)
Pλj
i=1+
P
i:Ti<tj
wgi (tj)δiI(i=2). (5.13)
The above equation can be further simplified as
k∏
j=1
(1− sj)
P
i:Ti=tj
δiI(i=1) · (sj)
P
i:Ti≥tj −
P
i:Ti=tj
δiI(i=1), (5.14)
where we utilize the fact that∑
i:Ti≥tj =
∑k
l=j{
∑λl
i=1 +
∑
i:Ti=tl
δiI(i = 1) +
∑
i:Ti<tl
wgi (tl)δiI(i = 2)}.
In (5.14), we take the log likelihood first, and then compute the first derivative with respect
to sj . So each sj is maximized individually by the binomial estimate
sˆj =
P
i:Ti≥tj −
P
i:Ti=tj
δiI(i=1)P
i:Ti≥tj
= 1− ej
Y ′j−1
.
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Therefore, the survival function is estimated by
Ŝ ′1j (t) =
 1 if t < t1∏
tj≤t
[1− ej
Y ′j−1
] if t1 ≤ t
. (5.15)
Thus, the adjusted survival function is the MLE of the pseudo-likelihood.
5.4.2 MLE of Pseudo-likelihood for Positive Correlation
For data with positive correlation, let pi denote the weight for the ith person. A pseudo-
likelihood with respect to S(t) (here S(t) refers to the adjusted survival S ′(t)) is defined as:
n∏
i=1
[Si(Ti − 0)− Si(Ti)]δiI(i=1)[Si(Ti)](1−δi)[Si(Ti − 0) − Si(Ti)]δiI(i=2)pi[Si(Ti)]δiI(i=2)(1−pi),
(5.16)
Following the approach of the previous proof, we can rewrite this pseudo-likelihood into the
Kaplan-Meier setting, and then further simplify it as
k∏
j=1
(Sj−1 − Sj)
P
i:Ti=tj
δiI(i=1)+
P
i:tj−1<Ti≤tj
δiI(i=2)pi × (Sj)
Pλj
i=1 × (Sj)
P
i:tj−1<Ti≤tj
δiI(i=2)(1−pi).
Utilizing the properties of the Kaplan-Meier estimator, the above equation is equal to
k∏
j=1
(1−sj)
P
i:Ti=tj
δiI(i=1)+
P
i:tj−1<Ti≤tj
δiI(i=2)pi(sj)
P
i:Ti≥tj
−
P
i:Ti=tj
δiI(i=1)−
P
i:tj−1<Ti≤tj
δiI(i=2)pi,
(5.17)
where we utilize the fact that∑
i:Ti≥tj
=
∑k
l=j{
∑λl
i=1 +
∑
i:Ti=tl
δiI(i = 1) +
∑
i:tl−1<Ti≤tl
δiI(i = 2)}.
In the equation (5.17), we compute the log likelihood first and then obtain the first
derivative with respect to sj. The MLE of sj then has the form
sˆj =
∑
i:Ti≥tj
−∑i:Ti=tj δiI(i = 1) −∑i:tj−1<Ti≤tj δiI(i = 2)pi∑
i:Ti≥tj
= 1− ej + e
′
2j
Yj−1
. (5.18)
Therefore, the adjusted survival function for the positive correlation Sˆ ′1j (t) is the MLE of
the pseudo-likelihood.
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5.5 INFERENCE TEST
When we try to compare the summary function of the cause of interest between two groups
(for example, the treatment group vs. the control group in a cancer study), our primary goal
is to compare the treatment effect on cancer survival and we do not care about competing
risks, such as death due to old age and other causes. Thus, we can use our adjusted survival
function for testing the differences between the two groups. We know that the log rank test
is the most powerful test for survival data with proportional hazards. In our case, we can
adapt the idea of the log rank test since the adjusted survival function (S ′r(t)) can be treated
as the traditional survival function. Therefore, in our modified log rank test, we can test the
equality of two S ′r(t)s.
Consider the hypothesis
H0 : S
′r
1 (t) = S
′r
2 (t) for all t ≤ τ
Ha : S
′r
1 (t) 6= S ′r2 (t) for some t ≤ τ,
where τ is the largest time at which both groups have at least one subject at risk.
Here we start with the inference test for negative correlation. Let dj = dj1 + dj2 and
Y ′j = Y
′
j1 + Y
′
j2 be the number of deaths and the adjusted number at risk at time tj, j =
1, 2 · · · , D. Based on Klein and Moeschberger (2003), our modified log-rank test is
G =
D∑
j=1
{dj1 − Y ′j1(
dj
Y ′j
)}. (5.19)
Note that at each time, tj, the test statistic is a multinomial random variable with parameters
dj and pj =
Y ′j1
Y ′j
. In other words, conditional on dj, dj1 has a hypergeometric distribution.
So the variance of G is
V ar(G) =
D∑
j=1
Y ′j1
Y ′j
(1− Y
′
j1
Y ′j
)(
Y ′j − dj
Y ′j − 1
)dj. (5.20)
The adjusted log-rank test is proposed as Z = G√
V ar(G)
, which has a standard normal
distribution for large samples when H0 is true. Thus, H0 is rejected if |Z| ≥ Zα/2 at an α
level, where Zα/2 is the critical value in the normal distribution.
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For data with positive correlation, our modified log-rank test has this form
G =
D∑
j=1
{d′j1 − Yj1(
d′j
Yj
)}, (5.21)
and the variance of G is
V ar(G) =
D∑
j=1
Yj1
Yj
(1− Yj1
Yj
)(
Yj − d′j
Yj − 1 )d
′
j. (5.22)
It should be noted that the variance formula we give is problematic due to the fact of
Y ′j , Y
′
j1, d
′
j, and d
′
j1 may not be integers. In the usual log rank test, both the number at risk
and the number of deaths are integers. In our modified log rank test, we use the “adjusted”
number at risk or “adjusted” number of deaths, and these quantities are fractional numbers.
The impact of these non-integer items on the variance formula needs to be further studied.
5.6 SIMULATION STUDIES
Because of the unknown features of the auxiliary variables, it is difficult to perform simulation
studies for the adjusted survival function with various correlations. Here we only evaluate the
performance of the adjusted survival function under the case of perfect negative correlation.
5.6.1 Performance of the Adjusted Survival Estimators
A simulation study was carried out to examine the performance of the estimators of the
mean, variance and associated confidence intervals in simulated samples with limited size.
The dependence structure between event 1 and event 2 was modeled as: (1) Let T1 and T2
denote two lognormally distributed random variables, where Tj = e
Yj and (Y1, Y2) follows a
bivariate normal distribution. Let uj and σj denote the mean and standard deviation of Yj;
and let u1 = u2 = 0, σ1 = σ2 = 1. (2) We transformed the correlation ρ between Y1 and Y2
into the Spearman correlation r = (6/pi)arcsin(ρ/2), such that this number was both the
Spearman correlation between Y1 and Y2 as well as between T1 and T2; (3) Three different
correlations were studied, ρ = 0, 0.5,−0.5. Independent censoring was generated from a
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uniform distribution, and two censoring rates were used, 0.15, 0.30. The sample size was set
at 100 and 500 samples were generated. Three time points were used, t0 = 0.5, 1.0, 1.5.
We calculated the mean, variance, and 95% confidence interval from the sample, and
compared them with the values we obtained from our formula. The results are displayed
in Table 5. Under different correlation structures, the estimator of adjusted survival seems
unbiased at each time point for both censoring rates. Although the variance estimator
appears to be slightly biased for some of the cases, the 95% confidence interval calculated
from our estimator had good coverage for practical purposes.
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Table 5. Performance of the Adjusted Survival Estimators
Correlation Censoring Time point Mean var Mean Coverage of
ρ rate t0 S
′1(t0) (Sˆ
′1(t0)) (Sˆ
′1(t0)) (v̂ar(Sˆ
′1(t0)) 95% C.I.
0
0.15
0.5 0.797 0.800 0.00154 0.00174 95%
1.0 0.630 0.633 0.00266 0.00261 95%
1.5 0.565 0.567 0.00314 0.00297 93%
0.30
0.5 0.822 0.820 0.00159 0.00178 95%
1.0 0.652 0.654 0.00279 0.00302 95%
1.5 0.565 0.577 0.00293 0.00345 94%
0.5
0.15
0.5 0.831 0.830 0.00143 0.00152 95%
1.0 0.679 0.680 0.00234 0.00242 95%
1.5 0.605 0.604 0.00270 0.00272 95%
0.30
0.5 0.845 0.847 0.00143 0.00151 95%
1.0 0.695 0.701 0.00280 0.00269 91%
1.5 0.620 0.622 0.00333 0.00320 93%
-0.5
0.15
0.5 0.771 0.779 0.00184 0.00188 91%
1.0 0.591 0.593 0.00287 0.00277 93%
1.5 0.526 0.528 0.00303 0.00294 93%
0.30
0.5 0.786 0.795 0.00220 0.00200 88%
1.0 0.594 0.605 0.00347 0.00330 90%
1.5 0.522 0.536 0.00400 0.00365 87%
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5.6.2 Equivalence of Adjusted Survival Function and 1-CIF
In this section, we performed simulation studies to compare our adjusted survival function
to 1-CIF. Samples are generated as the previous simulation study and a sample size of 1000
was used. Three different correlations were studied, ρ = 0, 0.5,−0.5, and the censoring rate
was 0.15, 0.30.
The simulation results are shown in Fig 8-10. The adjusted survival functions are close
to 1-CIF for different correlations and censoring rates, indicating that the two functions are
similar under these scenarios.
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Figure 8. Comparison of the estimated adjusted survival function and the 1-CIF with cor-
relation rate ρ = 0.
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Figure 9. Comparison of the estimated adjusted survival function and the 1-CIF with cor-
relation rate ρ = 0.5.
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Figure 10. Comparison of the estimated adjusted survival function and the 1-CIF with
correlation rate ρ = −0.5.
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5.7 ANALYSIS OF EMPHYSEMA DATA
The primary goal of the NETT study is to determine the role, safety, and effectiveness
of bilateral lung volume reduction surgery (LVRS) for the treatment of emphysema. In
the NETT trial, eligible patients are randomized into two groups: a group using medical
treatment only (N=610) and a group undergoing surgery along with medical treatment
(N=608). Comparing the two groups, no significant survival benefit was shown in the LVRS
with medical treatment group. However, the health-related quality of life (HRQL) tends to
be improved for the patients in the surgery group, and more patients experienced HRQL
improvement in the LVRS group than in the medical treatment only group (Figure 11).
As we mentioned earlier, the main event of interest is improvement in HRQL, while death
before reaching HRQL is a competing risk. The goal is to estimate the probability of HRQL
improvement for each of the two groups and to compare the probability difference between
the two groups.
Figure 12 shows that the bounds for the probability of HRQL improvement for each of
the two groups, and 1- adjusted survival function (perfectly negative) were almost coincident
with the CIF curves (the lower bound). If the HRQL improvement and death before reaching
HRQL are perfectly negatively related, then the probability of improvement should be the
lower bound; if the risks are independent, the probability of improvement is the upper bound
(SKM). Assuming the unknown negative dependence between two events because those who
died had worse HRQL compared to those who lived, our proposed adjusted survival function
was applied to obtain an estimated probability of HRQL improvement after removing the
effect of the competing event. The 1- adjusted survival function fell between the upper and
lower bound, and our estimated probability of HRQL improvement is significantly different
between the two groups (Z=15.2, P < 0.0001). Therefore, the LVRS procedure has shown
significant benefit to HRQL improvement based on our proposed approach.
To construct the generalized weight for the event 2 subjects (wg(t)), the estimated proba-
bility of experiencing event 1 for each event 2 person was obtained from the logistic regression
with a dataset excluding the event 2 persons, with three auxiliary variables were included in
the regression model: upper lobe (ul), maximum exercise capacity (maxcat), and treatment
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group. In the LVRS group, there are 151 event 2 subjects, among them the 39 persons have
missing auxiliary variables (ul and maxcat). In the medical treatment only group, 44 out of
the 215 event 2 subjects have missing auxiliary variables. For event 2 subjects with miss-
ing auxiliary variables, we imputed their probability with the mean predicted probability
of the group (0.76 for the LVRS group, 0.34 for the medical treatment only group). The
Kaplan-Meier estimator was used as an inverse probability of censoring weighted average.
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Figure 11. Histogram of time to improvement for each of the two groups.
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Figure 12. Comparison of the estimated 1-KM, 1-adjusted survival function and the CIF for
each of the two groups.
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5.8 DISCUSSION
In survival analysis with competing risks, two types of questions are usually of interest: the
time to event for each cause or the time to event focused on one primary cause. Currently, the
cumulative incidence function (CIF) is the most widely used summary function to address
these two types of questions. However, the CIF addresses the marginal failure probability of
interest and therefore the resulting function only presents partial information if the failure
probabilities of the competing events do not present simultaneously. In many cases, our
main interest is focused on one primary event, and the presence of competing risks only
make the situation complicated. A single summary function of the “net probability” is more
interpretable and appropriate. It is challenging for estimating the survival probability of one
event when we lose the information of the potential failure time of the persons experiencing
competing events. Without “auxiliary variables”, the missing failure time due to the com-
peting events remains unidentifiable given the survival time and event. In order to recover
the missing survival information for persons experiencing competing events, we assume that
the auxiliary variables are sufficient, which means that given the auxiliary variables, the
ith event 2 person’s probability of experiencing event 1 at time t does not depend on the
potential missing failure time, t∗i . The discussion of sufficiency of the auxiliary variables can
also be found in Satten et al’s paper (2001). However, this assumption is untestable and
questionable. The violation of this assumption can lead to invalid or biased estimates of the
survival probability.
Unlike other net survival probability estimators, our proposed adjusted survival function
only targets the event 2 subjects instead of adding weight to all censoring subjects (Robins
and Finkelstein, 2000; Grunkemeier et al, 2007). The advantage of our approach is: we treat
the true censoring and dependent censoring differently, therefore, only the dependent cen-
soring due to the competing risks needs to be taken care of. Moreover, our adjusted survival
functions have properties and inference test similar to the traditional survival functions,
leading to easy interpretation and clear understanding. However, for our adjusted survival
function, we derived a different formula for negative correlation and positive correlation.
Therefore, we have to assume the dependece structures between events before the analysis.
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This assumption should be based on the prior knowledge of the events and professional opin-
ions. Mis-specifying the correlation can lead to severe bias in the estimates. The practical
procedure for determining the correlation (negative or positive) needs to be studied in the
future.
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6.0 SUMMARY AND FUTURE WORK
There are two parts for this dissertation: one is to construct an adjusted cumulative inci-
dence function (ACIF) if the data involve unbalanced confounding variables and another
is to construct an adjusted survival function if the data involve administrative censoring
(independent censoring) and censoring due to competing risks (dependent censoring).
For the first part, the ACIF has been developed and its asymptotic properties have
been derived. The ACIF applies the inverse probability weighting technique to the overall
survival and cause-specific hazard functions in the naive CIF estimate. The ACIF estimate
is proving to be unbiased and the variance formula is derived. An inference procedure to
test the equality of two ACIFs is given. The test statistic is based on stochastic ordering of
the functions. The performance of the ACIF estimators has been evaluated via simulation
studies. In future studies, the performance of the test will be assessed via simulation studies
and the test will be generalized from comparing 2 groups to k groups.
For the second part, a series of adjusted survival functions has been developed for esti-
mating the “net” survival probability of interest event. First, for risks with perfect negative
correlation, we proposed an adjusted survival function using inverse probability of censoring
weight at each time point to remove the effect of dependent censoring due to competing
risks. We showed that this adjusted survival function is equivalent to 1-CIF. Second, using
Peterson’s upper bound and the KM survival estimate, we constructed the bounds for neg-
atively correlated risks. The adjusted survival function was created by using the adjusted
number at risk, which incorporated the information recovered from the auxiliary variables for
the event 2 subjects and the inverse censoring weight. Third, using Peterson’s lower bound
and the KM survival estimate, we introduced the bounds for risks with positive correlation.
The generalized adjusted survival function was constructed by using the adjusted number
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of deaths, which also incorporated the recovered information of the event 2 subjects from
auxiliary variables. The properties of these adjusted survival functions have been derived.
A generalized log rank test is proposed to test the equality of two adjusted survival func-
tions. The performance of these generalized log rank tests will be studied carefully in the
future. Also, the performance of our approach will be assessed via simulation studies and
by comparing it with other current methods.
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APPENDIX
PROOFS FOR THE ACIF
A.1 MEAN OF THE ACIF
Ej[Iˆ
rw
k (tj)] = Ej
{
j∑
j′=1
λˆrwk (tj′) · Sˆwk (tj′−1)
}
= Ej
[
j∑
j′=1
Ej′−1
{
λˆrwk (tj′) · Sˆwk (tj′−1)| information up to time tj′−1
}]
= Ej
[
j∑
j′=1
λˆrwk (tj′) · Ej′−1
{
Sˆwk (tj′−1)| information up to time tj′−1
}]
= Ej
[
j∑
j′=1
λˆrwk (tj′) · Swk (tj′−1)
]
=
j∑
j′=1
[
Swk (tj′−1) · Ej
{
λˆrwk (tj′)
}]
=
j∑
j′=1
[
Swk (tj′−1) · Ej
{
drwj′k
Yj′k
}]
=
j∑
j′=1
[
Swk (tj′−1) ·
λrwk (tj′) · Yj′k
Yj′k
]
=
j∑
j′=1
λrwk (tj′) · Swk (tj′−1)
= Irwk (tj).
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A.2 VARIANCE AND COVARIANCE OF THE ACIF
V ar
{
λˆrwi Sˆ
w(ti−1)
}
= V ar
[
Ei−1
{
λˆrwi Sˆ
w(ti−1)| information up to time ti−1
}]
+ E
[
V ari−1
{
λˆrwi Sˆ
w(ti−1)| information up to time ti−1
}]
= V ar
[
λˆrwi Ei−1
{
Sˆw(ti−1)
}]
+ E
[
(λˆrwi )
2V ari−1
{
Sˆw(ti−1)
}]
= {Sw(ti−1)}2 · V ar(λˆrwi ) + V ari−1
{
Sˆw(ti−1)
}
· E(λˆrwi )2.
If the probabilities of treatment, pi, are known, then from Xie and Liu (2005) we can prove
that
V ar(λˆrwi ) =
λrwi (1− λrwi )
Mi
.
Moreover, if maxi:Ti≥tj(1/pi)/
∑
i:Ti≥tj 1/pi → 0, then the variance of the adjusted Kaplan-
Meier function can be estimated and therefore
V ari−1
{
Sˆw(ti−1)
}
= {Sw(ti−1)}2
i−1∑
l=1
1− sw(tl)
Mlsw(tl)
and
E(λˆrwi )
2 = V ar(λˆrwi ) +
{
E(λˆrwi )
}2
=
λrwi (1− λrwi )
Mi
+ (λrwi )
2,
where Mi = (
∑
j:Tj≥ti 1/pj)
2/
∑
j:Tj≥ti(1/pj)
2 and sw(tl) = S
w(tl)/S
w(tl−1). With these
estimates, the ACIF variance estimator has the form
V̂ ar
{
λˆrwi Sˆ
w(ti−1)
}
=
{
Sˆw(ti−1)
}2
(λˆrwi )
2
[
1− λˆrwi
Miλˆrwi
+
{
i−1∑
l=1
1− sˆw(tl)
Mlsˆw(tl)
}(
1− λˆrwi
Miλˆrwi
+ 1
)]
.
If we let i < i′, then the ACIF covariance estimator is
Cov
{
λˆrwi Sˆ
w(ti−1), λˆrwi′ Sˆ
w(ti′−1)
}
= E
{
λˆrwi Sˆ
w(ti−1) · λˆrwi′ Sˆw(ti′−1)
}
− E
{
λˆrwi Sˆ
w(ti−1)
}
E
{
λˆrwi′ Sˆ
w(ti′−1)
}
= E
[
λˆrwi λˆ
rw
i′ sˆ
w(ti) · · · sˆw(ti′−1) ·
{
Sˆw(ti−1)
}2]
︸ ︷︷ ︸
(1)
−λrwi Sw(ti−1) · λrwi′ Sw(ti′−1).
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Part (1) can be further simplified as
E
{
Ei−1
[
λˆrwi λˆ
rw
i′ sˆ
w(ti) · · · sˆw(ti′−1) {Sw(ti−1)}2 | information up to time ti−1
]}
= E
{
λˆrwi λˆ
rw
i′ sˆ
w(ti) · · · sˆw(ti′−1) · Ei−1
[{Sw(ti−1)}2]}
= E
{
λˆrwi λˆ
rw
i′ sˆ
w(ti) · · · sˆw(ti′−1) ·
[
V ar
{
Sˆw(ti−1)
}
+ E2i−1 {Sw(ti−1)}
]}
= E
[
λˆrwi λˆ
rw
i′ sˆ
w(ti) · · · sˆw(ti′−1) · {Sw(ti−1)}2
{
i−1∑
l=1
1− sw(tl)
Mlsw(tl)
+ 1
}]
= λrwi′ {sw(ti+1) · · · sw(ti′−1)}Sw(ti−1)2{
i−1∑
l=1
1− sw(tl)
Mlsw(tl)
+ 1} · E{λˆrwi · sˆw(ti)}︸ ︷︷ ︸
(2)
.
If we split the total number of deaths at time t into death due to event r and death due to
the non-events r¯, dwi = d
rw
i + d
r¯w
i , then part (2) becomes
E{λˆrwi · sˆw(ti)}
= E{d
rw
i
Y wi
(1− d
rw
i + d
r¯w
i
Y wi
)}
= E(λˆrwi )− E
(drwi )
2 + drwi · dr¯wi
(Y wi )
2
= λrwi −
V (drwi ) + E
2(drwi ) + E(d
rw
i ) · E(dr¯wi )
(Y wi )
2
= λrwi − λrwi (
1− λrwi
Mi
+ λrwi + λ
r¯w
i )
= λrwi (1− λwi −
1− λrwi
Mi
)
= λrwi {sw(ti)−
1− λrwi
Mi
}
= λrwi s
w(ti){1− 1− λ
rw
i
Misw(ti)
}.
Thus, the covariance of the ACIF and its estimate have the form
Cov
{
λˆrwi Sˆ
w(ti−1), λˆrwi′ Sˆ
w(ti′−1)
}
= λrwi λ
rw
i′ S
w(ti−1)Sw(ti′−1)[{
i−1∑
l=1
1− sw(tl)
Mlsw(tl)
+ 1}{1− 1− λ
rw
i
Misw(ti)
} − 1]
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and
Ĉov
{
λˆrwi Sˆ
w(ti−1), λˆrwi′ Sˆ
w(ti′−1)
}
= λˆrwi λˆ
rw
i′ Sˆ
w(ti−1)Sˆw(ti′−1)[{
i−1∑
l=1
1− sˆw(tl)
Mlsˆw(tl)
+ 1}{1− 1− λˆ
rw
i
Misˆw(ti)
} − 1],
respectively.
A.3 DISTRIBUTION OF THE TEST STATISTIC
Z0 To show that the test statistic Z0 = WI/
√
V ar(WI) has a standard normal distribution
for large samples under the null hypothesis, we begin by showing that
√
n{Iˆrw(t)−Irw(t)}(t ≤
τ) is asymptotically equivalent to a sum of i.i.d. mean zero random variables. We then utilize
Theorem 4.1 of Pepe (1991) to construct the formula of the consistent variance estimator
and the asymptotically normal test.
Here we try to extend the usual counting process technique to the setting of the weighted
survival data. We define Nwir(t) = wiI[Ti ≤ t, δi = 1, i = r] and Nwr (t) =
∑n
i=1Ni(t) =∑n
ti≤t δi · wi · I[i = r], where r denotes the cause type, i denotes as the ith individual. Let
M i′r (t) = N
iw
r (t)−
∫ t
0
wiλ
w
r (s)ds
and we can show that M i′r (t) is a martingale, that is,
E{dM i′r (t)|Ft−} = E{[dN iwr (t)− d{
∫ t
0
wiλ
w
r (s)ds}]|Ft−}
= E{dN iwr (t)|Ft−} − E{wiλwr (t)dt|Ft−}
= 0,
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where Ft− denotes the history, or filtration, at an instant just prior to t. The above expec-
tation is equal to 0since λwr (t) has a fixed value given Ft−. Thus, M
′
r(t) =
∑n
1 M
i′
r is also a
martingale, and
√
n
{
Iˆrw(t)− Irw(t)
}
=
√
n[
∫ t
0
Sˆw−(s)
Y wr (s)
I{Y wr (s) > 0}dNwr (s)−
∫ t
0
Sw(s)λwr (s)ds]
=
√
n
∫ t
0
Sˆw−(s)
Y wr (s)
I{Y wr (s) > 0}dM ′r(t) +
√
n
∫ t
0
Sˆw−(s)
Y wr (s)
I{Y wr (s) > 0}d{
∫ t
0
Y wr (s)λ
w
r (s)ds}
− √n
∫ t
0
Sw(s)λwr (s)ds
=
√
n
∫ t
0
Sˆw−(s)
Y wr (s)
I{Y wr (s) > 0}dM ′r(t) +
√
n
∫ t
0
Sˆw(s)I{Y wr (s) > 0}λwr (s)ds−
√
n
∫ t
0
Sw−(s)λwr (s)ds
=
√
n
∫ t
0
Sˆw−(s)
Y wr (s)
I{Y wr (s) > 0}dM ′r(t) +
√
n
∫ t
o
{Sˆw(s)− Sw(s)}λwr (s)ds
− √n
∫ t
0
Sˆw−(s)I{Y wr (s) = 0}λwr (s)ds.
The third term converges to 0 in probability since P{Y wr (t) = 0} → 0; the first term is asymp-
totically equivalent to (
√
n)−1
∑n
i=1
∫ t
0
{ Sw(s)
Y wr (s)/n
}dM i′r (s) and the second term is asymptoti-
cally equivalent to (
√
n)−1
∑n
i=1X
i
s(s)λ
w
r (s)ds. Thus, we can show that
√
n{Iˆrw(t)− Irw(t)}
is asymptotically equivalent to (
√
n)−1
∑n
i=1X
i
Iwr
(t), where
X iIwr (t) =
∫ t
0
{ S
w(s)
Y wr (s)/n
}dN iwr (s)−
∫ t
0
nSw(s)λwr (s)ds +
∫ t
0
X iS(s)λ
w
r (s)ds.
Based on a Taylor series expansion, Corollary 2.1 of Pepe (1991) also holds for our ACIF.
Therefore according to Theorem 4.1 of Pepe, we have:
WI =
√
n1n2
n1 + n2
·
∫ τ
0
K(t)
{
Iˆrw1 (t)− Iˆrw2 (t)
}
dt→d N(0, σ2WI)
and
σˆ2WI =
2∑
j=1
n3−j
(n1 + n2)nj
nl∑
i=1
{
∫ τ
0
Kˆ(u)Xˆ iIwr (u)du}2 →P σ2WI .
If
∫ τ
0
K(u){Iˆrw1 (u)− Iˆrw2 (u)}du 6= 0, then a test based on WI/
√
σˆ2WI and its asymptotic null
distribution is consistent.
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